Navigation Links
Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
Date:1/9/2008

- Former CEO David Shaw Named Executive Chairman and Chairman of the Board

-

CLINTON, N.J., Jan. 9 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biopharmaceutical company, announced today that Daniel Tasse has been appointed President and Chief Executive Officer. Mr. Tasse succeeds David Shaw, who has served as Chairman and interim CEO since the creation of Ikaria Holdings in March 2007 and will now serve as Executive Chairman and Chairman of the Board.

Mr. Shaw commented, "Daniel is an outstanding fit for the Ikaria opportunity, and vice versa. He has extensive executive management experience in 'academy companies' in the pharmaceutical and life sciences industry, with highly relevant expertise in R&D management, marketing and sales, and other functions in domestic and international markets. We expect to benefit strategically and operationally from Daniel's many years of involvement in both drugs and devices across many therapeutic areas and healthcare settings, including critical care. His leadership capabilities and his knowledge of in- hospital markets will be particularly valuable as Ikaria continues to build an exceptionally strong capability to serve the needs of critically ill patients."

Daniel Tasse stated, "The formation of Ikaria last year created a company with the potential to redefine the critical care industry. With Ikaria's industry-leading INOmax(R) product and a pipeline of unique therapeutic compounds and numerous business development and R&D opportunities, we have a very exciting and unique opportunity available to us. I feel very fortunate to join this team in a leadership position with the goal of building a legendary company in the years ahead."

Mr. Tasse most recently served as the General Manager of Baxter International's $2 billion Pharmaceuticals & Technologies business, a division created by integrating the company's Anesthesia, Critical Care and BioPharma Solutions Business units. Prior to his tenure at Baxter International, Mr. Tasse held management positions at GlaxoSmithKline and Upjohn. He has a B.Sc. in Biochemistry from the University of Montreal.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations for the critically ill. The company's product, INOmax(R) (nitric oxide) for inhalation, is an FDA- approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns. The drug also is approved by regulatory authorities and used in Canada, Europe, Australia and Latin America. In addition to marketing and selling its INOmax product, Ikaria is engaged in both Phase II trials with Covox(R) (carbon monoxide) for inhalation and Phase I trials with hydrogen sulfide (H2S) for various indications. Ikaria has a staff of over 300 people and is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen, LA. For more information on Ikaria, please visit http://www.ikaria.com.

Contacts

Matthew Bennett

Ikaria

908-238-6673

matthew.bennett@ikaria.com

Jason Rando/Catherine Bright

The Ruth Group

646-536-7025/7013

jrando@theruthgroup.com

cbright@theruthgroup.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
2. Ikaria Founding Scientist Named 2007 MacArthur Fellow
3. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
4. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
5. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
6. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
7. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
8. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
11. SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):